共 74 条
[1]
Ryan CJ(2010)Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J Clin Oncol 2 23-25
[2]
Smith MR(2016)Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide Clin Pharmacokinet 26 761-768
[3]
Fong L(2006)A validated liquid chromatographic–tandem mass spectroscopy method for the quantification of abiraterone acetate and abiraterone in human plasma J Chromatogr B. undefined undefined-undefined
[4]
Rosenberg JE(2013)β-Cyclodextrin sensitized spectrofluorimetry for the determination of abiraterone acetate and abiraterone J Fluoresc undefined undefined-undefined
[5]
Kantoff P(2016)A review on analytical methods for estimation of abiraterone acetate WJPMR undefined undefined-undefined
[6]
Raynaud F(2017)Analytical challenges in quantifying abiraterone with LC–MS/MS in human plasma Biomed Chromatogr. undefined undefined-undefined
[7]
Martins V(2012)Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC–MS/MS-ESI: application to a pharmacokinetic study Biomed Chromatogr. undefined undefined-undefined
[8]
Lee G(2013)Highly sensitive ultra-performance liquid chromatography–tandem mass spectrometry method for the determination of abiraterone in human plasma Anal Methods. undefined undefined-undefined
[9]
Kheoh T(2015)A HPLC-fluorescence method for the quantification of abiraterone in plasma from patients with metastatic castration-resistant prostate cancer J Chromatogr B. undefined undefined-undefined
[10]
Kim J(2018)Estimation of abiraterone in human plasma by liquid chromatography tandem mass spectrometry Acta Pharm Sci undefined undefined-undefined